Mandate

Vinge advises Fidelio Capital in the divestment of a minority stake in Odevo to CVC Capital Partners

Vinge has advised Fidelio Capital (“Fidelio”) and the other shareholders of Odevo Group (“Odevo”) in connection with the divestment of a minority shareholding to funds controlled by CVC Capital Partners (“CVC”). Fidelio, the existing management team and other minority shareholders of Odevo will retain a majority holding in the company.

Odevo has built an organisation which, supported by a bespoke tech-platform, helps residential property owners manage all aspects of their building, ranging from accounting, administration, invoicing and on-site services to renovations. The company was founded in Sweden in 2018 by the investment firm Fidelio and the current management team. Through organic growth and joining forces with more than 50 successful entrepreneurs across Europe and USA, Odevo has expanded the business more than 50x, now managing 1.4 million homes with more than 7,000 employees and an annual turnover of EUR 650 million. By welcoming CVC to the group of investors, Odevo takes yet another step on its international growth journey.

The transaction is subject to applicable regulatory and antitrust approvals.

Vinge’s team consisted of Jonas Bergström, Johanna Wiberg, Anna Jonsson, Elsie Nassar, Amanda Steen, Philip Moré, Lovisa Jonassen and Matilda Hamner (M&A), Nils Unckel and Anton Sjökvist (Financial Regulatory), Sebastian Örndahl and Alva Chambert (EU, Competition and Regulatory), Mathilda Persson, Jolene Reimerson and Siri Blomberg (Commercial Agreements, IT and GDPR), Rebecka Målquist (Intellectual Property), Mia Falk and Gulestan Ali (Compliance), Emelie Schoning, Emy Rydén, Gabriella Balbo and Ottilia Pettersson (Transaction Support Coordinators).

Read the client’s press release here.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025